Cardiol Therapeutics is expanding its Phase III MAVERIC trial after reaching its enrollment target, with topline results now anticipated in mid-2027. The company expects existing Capital to fund completion and maintain its cash runway into Q1 2028, giving investors a stated financing horizon for the pivotal study.

Key Highlights

  • MAVERIC’s primary efficacy measure is the time until a patient experiences a first new pericarditis recurrence.
  • The study uses a randomized, double-blind, placebo-controlled, multi-center design.
  • Cardiol Therapeutics has reached the enrollment goal for its Phase III MAVERIC trial and is expanding the study.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is a biotechnology company. It has reached the enrollment goal for its Phase III MAVERIC trial and is expanding the study, with topline results now anticipated in mid-2027.

MAVERIC Enrollment Moves Beyond Original Goal

The trial evaluates CardiolRx™ in patients with recurrent pericarditis. A blinded review found fewer recurrences than expected among randomized participants, an observation Cardiol views as encouraging. The MAVERIC Steering Committee recommended increasing enrollment to capture enough events for a stronger assessment of CardiolRx™’s potential to reduce recurrence risk. The company expects the expanded study and its completion to support the planned clinical readout in mid-2027. MAVERIC’s primary analysis will examine the time to a first new pericarditis recurrence, while the proportion of patients remaining free from a new episode at study end serves as a secondary endpoint.

Existing Capital Expected to Fund Trial Completion

Cardiol Therapeutics expects its existing capital to finance completion of MAVERIC. The company said the enrollment expansion is intended to provide the event count needed to preserve the trial’s planned statistical power. The study is evaluating whether CardiolRx™ can delay or prevent recurrence over time.